Trial of the Combined Use of Thiamine and Biotin in Patients With Huntington's Disease
Status:
Not yet recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
Evaluate the safety and tolerability of combined oral thiamine with biotin therapy in
patients with Huntington´s disease in mild to moderate stages and it is intended to evaluate
the biological effect of the treatment in the central nervous system of these patients using
as the main biomarker the increase in the level of thiamine monophosphate (TMP) in
cerebrospinal fluid (CSF) of these patients with Huntington Disease (HD) during a follow-up
period of one year.
Our main hypothesis is that combined thiamine-biotin oral therapy is a secure and
well-tolerated treatment, potentially capable of modifying the disease course or avoiding the
progression of symptoms in early-stages HD patients
Phase:
Phase 2
Details
Lead Sponsor:
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Collaborator:
Ciberned (Centro de Investigación Biomédica en Red)